FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 35 of 40
Feb 13, 2026The FDA’s decision not to review Moderna’s mRNA-based flu vaccine has elicited widespread responses from industry experts and regulators. This controversy occurs amid a broader crisis in communication within the FDA, affecting multiple companies and complicating the regulatory landscape for novel vaccine technologies.
Feb 11, 2026Medicaid funding has become a contentious political issue in the United States as the Trump administration implements significant budget reductions. This approach has pitted states with large urban populations against those with predominantly rural demographics, exposing the complex dynamics of healthcare policy across different geographic regions. Key stakeholders are debating the implications for healthcare access and equity.
Feb 11, 2026The refusal by the Food and Drug Administration to review Moderna's influenza vaccine application marks a significant regulatory event. This decision has generated discussion among industry stakeholders about the future direction and posture of the FDA toward vaccines and pharmaceutical approvals generally.
Feb 10, 2026Hims & Hers faces significant regulatory scrutiny after the FDA found numerous violations at one of its compounding pharmacies, raising concerns about product safety and quality control within the fast-growing telehealth and wellness company.
Feb 10, 2026Regenxbio, a prominent biotech firm specializing in gene therapy, received a setback as the FDA rejected its application for a rare-disease treatment. This decision reflects the stringent standards and challenges that gene therapies encounter in securing regulatory approval, especially in rare disease indications.
Feb 9, 2026The first year of the second Trump administration saw a reshaping of the FDA’s approach that directly impacted the pharmaceutical industry. Reviewing key trends from 2025 will provide valuable insights on how to navigate and capitalize on regulatory developments in 2026.
Feb 8, 2026Recent legislative and regulatory actions mark important steps in reforming pharmacy benefit management practices, crucial for employers managing prescription drug benefits. However, despite initial celebrations, the reforms fall short of addressing all employer concerns, notably failing to ban spread pricing, signaling that challenges remain in navigating the evolving PBM landscape.
Feb 7, 2026The ethics of gender-affirming care for minors has become a contentious issue following a Health and Human Services report. Critics argue about the use of scare tactics in recent commentaries, raising important questions about medical ethics, patient well-being, and public policy.
Feb 7, 2026The recent NFL Players Association-funded study on chronic traumatic encephalopathy (CTE) has sparked fierce criticism. A prominent scientist and NFL widow highlights concerns about the study's findings and implications, calling attention to the ongoing challenges of accurately understanding and addressing CTE among football players.
Feb 7, 2026The decision to discontinue the 340B rebate pilot program comes as providers voiced concerns over the financial and administrative burdens it would impose, potentially jeopardizing essential safety-net care. This regulatory development underscores the ongoing negotiation between policy objectives and practical provider realities in the healthcare system.
Feb 6, 2026As Alicia Jackson assumes leadership of ARPA-H, shifts in organizational priorities are evident with the recent layoffs affecting key personnel tasked with translating research advancements into commercial applications. This move signifies possible strategic recalibrations within the agency as it navigates its next phase.
Feb 6, 2026The TrumpRx platform represents a significant policy and market intervention in the pharmaceutical distribution landscape. By providing discounted access to drugs from major manufacturers, the platform aspires to influence drug pricing dynamics and consumer accessibility, though industry observers remain cautious about its long-term effects.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.